02.12.2010 • NewsSanofiGenzymeCVR

Sanofi Says CVR Interesting, No Comment on Genzyme

Sanofi-Aventis's CFO said a deal structure known as a contingent value right was interesting "in principle" but he declined to say if it was being discussed with bid target Genzyme.

"In principle, a contingent value right would be a way to bridge a gap when different parties have different ideas on valuations," Jerome Contamine told Reuters on the sidelines of an industry conference.

Genzyme CEO Henri Termeer, who is resisting Sanofi's $18.5 billion hostile bid, was quoted as saying on Nov. 26 that he was open to a deal linking his firm's value to the success of key drug Campath by using a contingent value right (CVR).

Company

Sanofi-Aventis Deutschland

Industriepark Höchst
65926 Frankfurt am Main
Germany

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read